Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Zacks Investment Research

25 Jun 2026, 14:55 UTC · 1h ago

NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Natera's Signatera test received PMDA approval in Japan for use in colorectal cancer patients in the adjuvant setting. — This is the first PMDA-approved molecular residual disease test in Japan, opening a significant new geographic market for the company.
+0.60
2
Natera plans to commercially launch Signatera in Japan by the end of 2026, pending pricing and reimbursement decisions. — Provides a clear timeline for revenue generation, though final profitability depends on critical reimbursement outcomes.
+0.40
3
Natera intends to submit muscle-invasive bladder cancer for regulatory approval in Japan as its next expansion step. — Indicates a pipeline for further growth and expansion of the product's utility beyond a single cancer type.
+0.30

Which stocks this story touches

6 related stories

Zacks Investment Research
2h ago
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
- biotech
- healthcare
Read

NTRA's Signatera Secures… — NTRA +1.00 | NewsImpactScreener

NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan

What matters in this story

ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan

What matters in this story

ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan

What matters in this story

Next reads from the same story arc

ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan

What matters in this story

Next reads from the same story arc

ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial